Infliximab
(Synonyms: 英夫利昔单抗,Avakine; CT-P13) 目录号 : GC19533
英夫利昔单抗是一种嵌合单克隆 IgG1 抗体，可特异性结合 TNF-α。
Cas No.:170277-31-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research[1][2]. So, infliximab is a medication used to treat patients with autoimmune and chronic inflammatory diseases[5].
infliximab has been also shown to improve insulin resistance[3]. In vitro,infliximab ameliorates TNF-alpha-induced insulin resistance in 3T3L1 adipocytes in vitro by restoring phosphorylation of key mediators of the insulin signaling pathway such as IRS-2 and AKT via PTP1B inhibition that in consequence improves insulin-dependent glucose uptake in these adipose cells[4]
Diabetic mice showed significant impairments in SNCV and MNCV at 8 weeks. Diabetic mice treated with saline showed no improvement in SNCV or MNCV at 12 weeks, whereas diabetic mice treated with infliximab showed significant improvement at this time (4 weeks after infliximab treatment). In conclusion a single injection of infliximab leads to marked improvement in diabetic neuropathy[7].Infliximab reduces the levels of serum insulin, fasting glucose and insulin resistance in patients with ankylosing spondylitis and rheumatoid arthritis[6]
References:
[1]. Lis K, Kuzawińska O, et,al. Tumor necrosis factor inhibitors - state of knowledge. Arch Med Sci. 2014 Dec 22;10(6):1175-85. doi: 10.5114/aoms.2014.47827. PMID: 25624856; PMCID: PMC4296073.
[2]. Yamakawa I, Kojima H, Terashima T, et,al.Inactivation of TNF-α ameliorates diabetic neuropathy in mice. Am J Physiol Endocrinol Metab. 2011 Nov;301(5):E844-52. doi: 10.1152/ajpendo.00029.2011. Epub 2011 Aug 2. PMID: 21810933; PMCID: PMC3213998.
[3]. Burska AN, Sakthiswary R, et,al. Effects of Tumour Necrosis Factor Antagonists on Insulin Sensitivity/Resistance in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. PLoS One. 2015 Jun 25;10(6):e0128889. doi: 10.1371/journal.pone.0128889. PMID: 26110878; PMCID: PMC4482317.
[4]. Méndez-García LA, Trejo-Millán F, et,al.Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro. Scand J Immunol. 2018 Nov;88(5):e12716. doi: 10.1111/sji.12716. Epub 2018 Oct 10. PMID: 30260514.
[5]. Antoni C, Krueger GG, et,al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005 Aug;64(8):1150-7. doi: 10.1136/ard.2004.032268. Epub 2005 Jan 27. PMID: 15677701; PMCID: PMC1755609.
[6]. Stagakis I, Bertsias G, et,al.Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther. 2012 Jun 12;14(3):R141. doi: 10.1186/ar3874. PMID: 22691241; PMCID: PMC3446524.
[7]. Yamakawa I, Kojima H, et,al.Inactivation of TNF-α ameliorates diabetic neuropathy in mice. Am J Physiol Endocrinol Metab. 2011 Nov;301(5):E844-52. doi: 10.1152/ajpendo.00029.2011. Epub 2011 Aug 2. PMID: 21810933; PMCID: PMC3213998.
英夫利昔单抗是一种嵌合单克隆 IgG1 抗体,可特异性结合 TNF-α。英夫利昔单抗阻止 TNF-α 与 TNF-α 受体（TNFR1 和 TNFR2）的相互作用。英夫利昔单抗具有用于自身免疫、慢性炎症性疾病和糖尿病神经病变研究的潜力[1][2]。因此,英夫利昔单抗是一种用于治疗自身免疫性疾病和慢性炎症性疾病的药物[5]。
英夫利昔单抗也被证明可以改善胰岛素抵抗[3]。在体外,英夫利昔单抗通过 PTP1B 抑制恢复胰岛素信号通路关键介质（如 IRS-2 和 AKT）的磷酸化,从而改善这些脂肪细胞中胰岛素依赖性葡萄糖摄取,从而改善 3T3L1 脂肪细胞中 TNF-α 诱导的胰岛素抵抗细胞[4]
糖尿病小鼠在 8 周时显示 SNCV 和 MNCV 显着受损。用盐水治疗的糖尿病小鼠在 12 周时未显示 SNCV 或 MNCV 改善,而用英夫利昔单抗治疗的糖尿病小鼠此时显示出显着改善（英夫利昔单抗治疗后 4 周）。总之,单次注射英夫利昔单抗可显着改善糖尿病神经病变[7]。英夫利昔单抗可降低强直性脊柱炎和类风湿性关节炎患者的血清胰岛素、空腹血糖和胰岛素抵抗水平[ 6]
| Cell experiment [1]: | |
|
Cell lines |
3T3L1 mature adipocytes |
|
Preparation Method |
Adipocytes were stimulated twice at zero and 60 minutes with 2 μmol L 1 insulin. Adipocytes were stimulated with 10 ng/mL infliximab at the beginning of the 2-hour in vitro assay. 3T3L1 adipocytes were collected every 20 minutes for 2 hour. |
|
Reaction Conditions |
10 ng/mL infliximab at the beginning of the 2-hour in vitro assay |
|
Applications |
Infliximab restores insulin-dependent glucose uptake, phosphorylation of the insulin signaling pathway and attenuates TNF-alpha-induced PTP1B activation in TNF-α-treated 3T3L1 adipocytes. |
| Animal experiment [2]: | |
|
Animal models |
Eight-week-old C57BL/6J (WT, TNF-α+/+) and TNF-α-deficient (TNFα−/−) mice of strain B6 |
|
Preparation Method |
Infliximab was injected into diabetic and normal mice for 4 weeks |
|
Dosage form |
Infliximab 10 μg/g in 100 μl saline for 4 weeks |
|
Applications |
Diabetic mice showed significant impairments in SNCV and MNCV at 8 weeks. Diabetic mice treated with saline showed no improvement in SNCV or MNCV at 12 weeks, whereas diabetic mice treated with infliximab showed significant improvement at this time (4 weeks after infliximab treatment). |
|
References: [1]. Méndez-García LA, Trejo-Millán F, Martínez-Reyes CP, Manjarrez-Reyna AN, Esquivel-Velázquez M, Melendez-Mier G, Islas-Andrade S, Rojas-Bernabé A, Kzhyshkowska J, Escobedo G. Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro. Scand J Immunol. 2018 Nov;88(5):e12716. doi: 10.1111/sji.12716. Epub 2018 Oct 10. PMID: 30260514. [2]. Yamakawa I, Kojima H, et,al.Inactivation of TNF-α ameliorates diabetic neuropathy in mice. Am J Physiol Endocrinol Metab. 2011 Nov;301(5):E844-52. doi: 10.1152/ajpendo.00029.2011. Epub 2011 Aug 2. PMID: 21810933; PMCID: PMC3213998./p> |
|
| Cas No. | 170277-31-3 | SDF | |
| 别名 | 英夫利昔单抗,Avakine; CT-P13 | ||
| 分子式 | C6428H9912N1694O1987S46 | 分子量 | 144188.23 |
| 溶解度 | 储存条件 | Store at -30°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.0069 mL | 0.0347 mL | 0.0694 mL |
| 5 mM | 0.0014 mL | 0.0069 mL | 0.0139 mL |
| 10 mM | 0.0007 mL | 0.0035 mL | 0.0069 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
-
Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet